Pharmaceutical Technology
MARCH 18, 2024
Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, a room temperature-stable drug for treating sickle cell disease.
Bio Pharma Dive
MARCH 18, 2024
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 18, 2024
The hair rising on the back of your neck, the gelid pool in the pit of your stomach, the flutter in your heart when a shadow shifts. Fear can be devastating, sickening, and, strangely, a lot of fun.
Bio Pharma Dive
MARCH 18, 2024
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
MARCH 18, 2024
The US FDA's ODAC has recommended Johnson & Johnson’s CARVYKTI to treat relapsed or refractory multiple myeloma (R/R MM).
Bio Pharma Dive
MARCH 18, 2024
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 18, 2024
Using GlobalData’s POLI & HTA database, analysis has been conducted that will provide insight into how the HTA landscape adapted between 2019 and 2023.
Pharma Times
MARCH 18, 2024
The centre will deliver free training, outreach materials and programmes
Pharmaceutical Technology
MARCH 18, 2024
Fennec’s Pedmarqsi/Pedmark is the only approved therapy to treat cisplatin-induced hearing loss in paediatric cancer patients.
pharmaphorum
MARCH 18, 2024
Discover the top 7 challenges faced by pharmaceutical and life sciences companies in achieving patient-centricity and engaging healthcare professionals (HCPs). Explore strategies to overcome these obstacles for successful outreach efforts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
MARCH 18, 2024
In the realm of clinical trials, participant retention is a cornerstone for success, offering robustness to the data collected and ensuring the validity of the trial outcomes.
pharmaphorum
MARCH 18, 2024
FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broader patient population.
Pharmaceutical Technology
MARCH 18, 2024
AdCom voted eight to three in favour of BMS and 2seventy bio’s CAR-T cell therapy, Abecma in triple-class exposed multiple myeloma patients.
BioPharma Reporter
MARCH 18, 2024
Eli Lilly is partnering with ecommerce titan Amazon to deliver its weight loss drug Zepbound straight to patientâs doors, in a bid to address ongoing shortages.
Pharmaceutical Technology
MARCH 18, 2024
Novartis has broken ground on the expansion of its $256m biopharmaceutical manufacturing facility in Singapore.
pharmaphorum
MARCH 18, 2024
Agreement has been reached in the EU on a European Health Data Space (EHDS), which will make it easier to exchange and access electronic health data.
Pharmaceutical Technology
MARCH 18, 2024
The US FDA has granted approval for Optinose’s XHANCE nasal spray for chronic rhinosinusitis without nasal polyps in adult patients.
pharmaphorum
MARCH 18, 2024
AI software designed to tackle missed appointments and reduce waiting lists will see its use by NHS England ramp up after a successful pilot deployment.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Commerce
MARCH 18, 2024
In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the positive signs from rising activity levels in biopharma M&A— and what the momentum may mean for industry dealmaking and partnership efforts in the months ahead.
pharmaphorum
MARCH 18, 2024
GSK's PD-1 inhibitor Jemperli improves overall survival when used first-line in an all-comer endometrial cancer trial
Fierce Pharma
MARCH 18, 2024
Kyowa Kirin’s bet on Orchard Therapeutics has paid off, furnishing the Japanese drugmaker with a newly approved gene therapy in the U.S. | The FDA on Monday gave a thumbs up to Lenmeldy as the first gene therapy in the U.S. for kids with certain types of metachromatic leukodystrophy (MLD).
pharmaphorum
MARCH 18, 2024
Bristol-Myers Squibb gets its $14bn takeover of Karuna Therapeutics over the finish line, taking control of schizophrenia candidate KarXT ahead of an FDA decision in September
Fierce Pharma
MARCH 18, 2024
Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is | Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger selloff, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering.
pharmaphorum
MARCH 18, 2024
Contineum Therapeutics joins IPO queue, seeking $150m for its pulmonary fibrosis and multiple sclerosis candidates
Pharmaceutical Technology
MARCH 18, 2024
CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension.
BioSpace
MARCH 18, 2024
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
MARCH 18, 2024
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Schizophrenia.
pharmaphorum
MARCH 18, 2024
Orchard's gene therapy for MLD finally gets US approval Jonah.
Pharmaceutical Technology
MARCH 18, 2024
Ulotaront hydrochloride is under clinical development by Sumitomo Pharma America and currently in Phase III for Generalized Anxiety Disorder (GAD).
BioPharma Reporter
MARCH 18, 2024
ReciBioPharm has partnered with pre-clinical gene therapy company GeneVentiv Therapeutics to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
306 
Let's personalize your content